Breast Cancer : Targets and Therapy最新文献

{"title":"Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer.","authors":"Yunxia Huang,&nbsp;Yi Guo,&nbsp;Qin Xiao,&nbsp;Shuyu Liang,&nbsp;Qiang Yu,&nbsp;Lang Qian,&nbsp;Jin Zhou,&nbsp;Jian Le,&nbsp;Yuchen Pei,&nbsp;Lei Wang,&nbsp;Cai Chang,&nbsp;Sheng Chen,&nbsp;Shichong Zhou","doi":"10.2147/BCTT.S408997","DOIUrl":"https://doi.org/10.2147/BCTT.S408997","url":null,"abstract":"<p><strong>Purpose: </strong>The emergence of genomic targeted therapy has improved the prospects of treatment for breast cancer (BC). However, genetic testing relies on invasive and sophisticated procedures.</p><p><strong>Patients and methods: </strong>Here, we performed ultrasound (US) and target sequencing to unravel the possible association between US radiomics features and somatic mutations in TNBC (n=83) and non-TNBC (n=83) patients. Least absolute shrinkage and selection operator (Lasso) were utilized to perform radiomic feature selection. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was utilized to identify the signaling pathways associated with radiomic features.</p><p><strong>Results: </strong>Thirteen differently represented radiomic features were identified in TNBC and non-TNBC, including tumor shape, textual, and intensity features. The US radiomic-gene pairs were differently exhibited between TNBC and non-TNBC. Further investigation with KEGG verified radiomic-pathway (ie, JAK-STAT, MAPK, Ras, Wnt, microRNAs in cancer, PI3K-Akt) associations in TNBC and non-TNBC.</p><p><strong>Conclusion: </strong>The pivotal network provided the connections of US radiogenomic signature and target sequencing for non-invasive genetic assessment of precise BC treatment.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/08/bctt-15-461.PMC10349575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.","authors":"Çağlar Ünal,&nbsp;Tolga Özmen,&nbsp;Ahmet Serkan İlgün,&nbsp;Çetin Ordu,&nbsp;Enver Özkurt,&nbsp;Naziye Ak,&nbsp;Gül Alço,&nbsp;Zeynep Erdoğan İyigün,&nbsp;Sevgi Kurt,&nbsp;Tomris Duymaz,&nbsp;Mehmet Alper Öztürk,&nbsp;Filiz Elbüken Çelebi,&nbsp;Kanay Yararbaş,&nbsp;Gürsel Soybir,&nbsp;Fatma Aktepe,&nbsp;Vahit Özmen","doi":"10.2147/BCTT.S421535","DOIUrl":"https://doi.org/10.2147/BCTT.S421535","url":null,"abstract":"<p><strong>Background: </strong>The minichromosome maintenance protein-2 (MCM-2) is a more sensitive proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM-2 and Oncotype DX recurrence score (ODX-RS) and determine an MCM-2 cutoff value in high-risk patients according to TAILORx risk categorization.</p><p><strong>Methods: </strong>Hormone receptor (HR) positive HER-2 negative early-stage breast cancer patients (pT1-2, pN0-N1, M0) who had ODX-RS were included in the study. According to the TAILORx trial, patients were divided into two groups with high (ODX-RS ≥26) and low risk (ODX-RS <26) in terms of ODX-RS. Formalin-fixed-paraffin-embedded tissues of patients were re-evaluated, and 3 µm sections were prepared for MCM-2 immuno-histochemical staining. The relationship between ODX-RS and the percentage of MCM-2 staining was evaluated in two groups. The ROC curve analysis was performed to determine the MCM-2 cut-off value for the TAILORx high-risk group (ODX-RS ≥26).</p><p><strong>Results: </strong>The mean MCM-2 value was significantly higher in the high-risk group [(60.2 ± 11.2 vs 34.4 ± 13.8, p < 0.001)]. In the multivariate analysis, MCM-2 (OR: 1.27, 95% CI: 1.08-1.49, p = 0.003) and progesterone receptor (PR) levels ≤10% (OR: 60.9, 95% CI: 4.1-89.7, p = 0.003) were found to be independent factors indicating a high-risk group. A one-unit increase in MCM-2 level increased the likelihood of being in the high-risk group by 1.27 times. In the ROC curve analysis, the optimal MCM-2 cut-off level was 50 (AUC: 0.921, sensitivity: 86.7%, specificity: 96.0%, p < 0.001).</p><p><strong>Conclusion: </strong>Our study is the first study in the literature to investigate the relationship between ODX-RS and MCM-2 levels in HR-positive HER-2 negative early breast-cancer patients. In this study, MCM-2 was an independent risk factor in identifying high-risk patients according to TAILORx risk classification. MCM 2 cut-off value (50) may help the decision on adjuvant chemotherapy in patients where the Oncotype DX test cannot be performed.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/9e/bctt-15-659.PMC10478780.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10178344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detecting the Frequency of c.5946delT Pathogenic Variant in the <i>BRCA2</i> Gene and Associated Risk Factors Among Breast Cancer Patients Visiting Felege Hiwot Referral Hospital and University of Gondar Comprehensive Specialized Hospital.","authors":"Nega Berhane,&nbsp;Zemene Chekol,&nbsp;Aynias Seid","doi":"10.2147/BCTT.S414360","DOIUrl":"https://doi.org/10.2147/BCTT.S414360","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is one of the most common cancers and the leading cause of death for women worldwide, and the problem is currently getting worse. In Ethiopia, it has become one of the most prevalent cancers, with high rates of morbidity and mortality. The <i>BRCA2</i> gene variant c.5946delT has been linked to a higher risk of developing breast cancer.</p><p><strong>Objective: </strong>The aim of the present study was to detect the presence of the c.5946delT pathogenic variant in the <i>BRCA2</i> gene and associated risk factors among breast cancer patients visiting FHRH and UoGCSH.</p><p><strong>Methods: </strong>A cross-sectional study was conducted from September 2021 to October 2022. Peripheral blood samples were collected from 100 patients with breast cancer, and gDNA was extracted using the salting-out method as per the protocol provided in the manufacturer's instructions. The <i>BRCA2</i> gene c.5946delT variant was detected using the PCR-RFLP technique. The data were analyzed using SPSS version 23. P≤ 0.05 was considered statistically significant.</p><p><strong>Results: </strong>In this study, we discovered that 2% of breast cancer patients had a c.5946delT pathogenic variant of the <i>BRCA2</i> gene. In addition, the results suggested that the c.5946delT pathogenic variant and age at diagnosis were significantly correlated. On the other hand, there was no significant association between inhabitance and family history for the c.5946delT variant.</p><p><strong>Conclusion: </strong>We have found out that breast cancer patients in the study area had the <i>BRCA2</i> gene variant c.5946delT, which suggests that this pathogenic variant is linked to breast cancer. Hence, assessing gene alterations using the PCR technique is one of the most effective early diagnostic strategies for breast cancer that should be used in hospitals in order to lower mortality.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/0a/bctt-15-421.PMC10289093.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9716698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk.","authors":"Sanjana Satish,&nbsp;Jessica F Moore,&nbsp;Jay M Littlefield,&nbsp;Ian J Bishop,&nbsp;Kristin E Rojas","doi":"10.2147/BCTT.S390664","DOIUrl":"https://doi.org/10.2147/BCTT.S390664","url":null,"abstract":"<p><p>This review aims to summarize and assess key studies investigating the relationship between hormonal contraception and breast cancer risk. Approximately two-thirds of breast cancers express the estrogen receptor, and long-term exposure to estrogen is a debated risk factor for breast cancer development. This hypothesis is based on prior studies looking at reproductive risk factors (endogenous estrogen exposure) along with hormone replacement therapy (exogenous hormone exposure). Historically accepted reproductive risk factors include age at menarche, age at first delivery, and parity. Exogenous hormone exposure encompasses both receipt of hormonal contraception and menopausal hormone replacement therapy. This review highlights the reported risks associated with the most common hormonal contraception methods including oral, transdermal, and transvaginal routes. Large observational studies of the past and more recent works are summarized highlighting gaps in knowledge. Several themes emerge: difficulty accounting for well-established risk factors in analyses of epidemiologic studies, challenges determining whether associations between hormonal contraception and breast cancer are due to the exogenous hormones themselves or to increased engagement with the medical system, and discrepancies between statistically significant and clinically significant risk, odds, and hazard ratios. Understanding the strengths and limitations of these studies will help providers in and outside of oncology support women making decisions regarding both cancer risk-reduction and family planning.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/04/bctt-15-227.PMC10040158.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9203399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation?","authors":"Selman Emiroglu,&nbsp;Enver Özkurt,&nbsp;Neslihan Cabıoglu,&nbsp;Abdullah Igci,&nbsp;Pinar Saip,&nbsp;Hulya Yazici,&nbsp;Tolga Ozmen,&nbsp;Vahit Ozmen,&nbsp;Mahmut Muslumanoglu,&nbsp;Mustafa Tukenmez","doi":"10.2147/BCTT.S395054","DOIUrl":"https://doi.org/10.2147/BCTT.S395054","url":null,"abstract":"<p><strong>Background: </strong>The optimal surgical therapy for newly diagnosed breast cancer with germline mutations in susceptibility genes is still uncertain for many physicians. In this study, we aimed to determine the efficacy of breast conserving surgery (BCS) in breast cancer patients with <i>BRCA1</i> or <i>BRCA2</i> mutation by assessing its outcomes and locoregional recurrence (LR) rates.</p><p><strong>Materials and methods: </strong>Seventy-five patients operated with BCS or mastectomy for breast cancer between 2006 and 2017 and had <i>BRCA1</i> or <i>BRCA2</i> mutation were included in the study. Effects of the performed breast surgery and clinicopathological characteristics on surgical outcomes, LR rates and survival were analyzed with showing the distribution of <i>BRCA1</i> and <i>BRCA2</i> germline mutations.</p><p><strong>Results: </strong>The median age of the patients was 42 years (20-77). <i>BRCA1</i> mutations were found in 46 (61.3%) patients and <i>BRCA2</i> mutations in 29 (38.7%) patients. Compared to <i>BRCA2</i> carriers, <i>BRCA1</i> carriers were more likely to have higher tumor grade (84.8% vs 44.8%; <i>p</i> = 0.001) and non-luminal subtype tumors (67.4% vs 13.8%; <i>p</i> = 0.001). A total of 44 (58.7%) patients underwent unilateral mastectomy and 31 (41.3%) patients underwent BCS. At a median follow-up time of 60 (12-240) months, LR was observed in 6 patients equally divided in both BCS and mastectomy groups. LR rates were slightly higher after BCS versus mastectomy (9.7% and 6.8%, respectively). Additionally, there were no statistically significant differences in disease-free survival (DFS) and disease-specific survival (DSS) rates after 10 years in the BCS group versus the mastectomy group (<i>p</i> = 0.117 and 0.109, respectively), but in fact, the rates were better in the BCS group.</p><p><strong>Conclusion: </strong>Our findings indicate that BCS may serve as an efficacious alternative to mastectomy for breast cancer patients with <i>BRCA1</i> or <i>BRCA2</i> mutation. Additionally, tumor size, lymph node positivity, and TNM stage should be taken into consideration for a better surgical decision-making.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/85/bctt-15-163.PMC9960707.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9369047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoter Methylation-Regulated Differentially Expressed Genes in Breast Cancer.","authors":"Samar Sindi,&nbsp;Norah Hamdi,&nbsp;Sabah Hassan,&nbsp;Magdah Ganash,&nbsp;Mona Alharbi,&nbsp;Najla Alburae,&nbsp;Sheren Azhari,&nbsp;Shadi Alkhayyat,&nbsp;Ayman Linjawi,&nbsp;Heba Alkhatabi,&nbsp;Aisha Elaimi,&nbsp;Ghadeer Alrefaei,&nbsp;Nouf Alsubhi,&nbsp;Aziza Alrafiah,&nbsp;Safiah Alhazmi","doi":"10.2147/BCTT.S408711","DOIUrl":"https://doi.org/10.2147/BCTT.S408711","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is one of the most common malignancies among women. Recent studies revealed that differentially methylated regions (DMRs) are implicated in regulating gene expression. The goal of this research was to determine which genes and pathways are dysregulated in breast cancer when their promoters are methylated in an abnormal way, leading to differential expression. Whole-genome bisulfite sequencing was applied to analyze DMRs for eight peripheral blood samples collected from five Saudi females diagnosed with stages I and II of breast cancer aligned with three normal females. Three of those patients and three normal samples were used to determine differentially expressed genes (DEG) using Illumina platform NovaSeq PE150.</p><p><strong>Results: </strong>Based on ontology (GO) and KEGG pathways, the analysis indicated that DMGs and DEG are closely related to associated processes, such as ubiquitin-protein transferase activity, ubiquitin-mediated proteolysis, and oxidative phosphorylation. The findings indicated a potentially significant association between global hypomethylation and breast cancer in Saudi patients. Our results revealed 81 differentially promoter-methylated and expressed genes. The most significant differentially methylated and expressed genes found in gene ontology (GO) are pumilio RNA binding family member 1 (<i>PUM1</i>) and zinc finger AN1-type containing 2B (<i>ZFAND2B</i>) also known as (<i>AIRAPL</i>).</p><p><strong>Conclusion: </strong>The essential outcomes of this study suggested that aberrant hypermethylation at crucial genes that have significant parts in the molecular pathways of breast cancer could be used as a potential prognostic biomarker for breast cancer.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/e0/bctt-15-435.PMC10332364.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9814448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses.","authors":"Yudi Jin,&nbsp;Ailin Lan,&nbsp;Yuran Dai,&nbsp;Linshan Jiang,&nbsp;Shengchun Liu","doi":"10.2147/BCTT.S407896","DOIUrl":"https://doi.org/10.2147/BCTT.S407896","url":null,"abstract":"<p><strong>Background: </strong>Recent studies have investigated the features of breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression or HER2-0 expression. However, the results were inconsistent. In this study, we investigated the differences in the pathological complete response (pCR) rate and disease-free survival (DFS) between HER2-low and HER2-0 BC patients and between subgroups.</p><p><strong>Methods: </strong>HER2-negative BC patients who received neoadjuvant chemotherapy between January 2013 and December 2019 in our hospital were retrospectively reviewed. First, the pCR rate and DFS were compared between HER2-low and HER2-0 patients and among different hormone receptor (HR) and HER2 statuses. Subsequently, DFS was compared between different HER2 status populations with or without pCR. Finally, a Cox regression model was used to identify the prognostic factors.</p><p><strong>Results: </strong>Overall, 693 patients were selected: 561 were HER2-low, and 132 were HER2-0. Between the two groups, there were significant differences in N stage (P = 0.008) and HR status (P = 0.007). No significant difference in the pCR rate (12.12% vs 14.39%, P = 0.468) or DFS was observed, independent of HR status. HR+/HER2-low patients had a significantly worse pCR rate (P < 0.001) and longer DFS (P < 0.001) than HR-/HER2-low or HER2-0 patients. In addition, a longer DFS was found in HER2-low patients versus HER2-0 patients among those who did not achieve pCR. Cox regression showed that N stage and HR status were prognostic factors in the overall and HER2-low populations, while no prognostic factor was found in the HER2-0 group.</p><p><strong>Conclusion: </strong>This study suggested that HER2 status is not associated with the pCR rate or DFS. Longer DFS was found only among patients who did not achieve pCR in the HER2-low versus HER2-0 population. We speculated that the interaction of HR and HER2 might have played a crucial role in this process.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/38/bctt-15-327.PMC10162099.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients' Needs?","authors":"Elisabeth M Jongbloed,&nbsp;Hedwig M Blommestein,&nbsp;Hannah M van Schoubroeck,&nbsp;John W M Martens,&nbsp;Saskia M Wilting,&nbsp;Carin A Uyl-de Groot,&nbsp;Agnes Jager","doi":"10.2147/BCTT.S387375","DOIUrl":"https://doi.org/10.2147/BCTT.S387375","url":null,"abstract":"<p><strong>Purpose: </strong>The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2- early breast cancer (EBC) has been approved by the US Food and Drug Administration (FDA). Pre-selection of patients with an immediate risk of recurrence within the group of clinically high risk patients using detection of minimal residual disease (MRD) using patient-informed circulating tumor DNA assays during follow-up could enhance efficacy. Here, we investigate the cost-effectiveness of the addition of two years abemaciclib in all high risk HR+, HER2- patients and in MRD-guided high risk patients only.</p><p><strong>Methods: </strong>Two semi-Markov models were developed to evaluate the cost-effectiveness of adding two years of abemaciclib compared to \"standard treatment\": 1) \"abemaciclib all\" and 2) \"MRD-guided abemaciclib\" using MRD-guidance. Data of the MonarchE trial were used to model the invasive disease-free survival (iDFS). Since iDFS and overall survival (OS) data of abemaciclib were currently limited, abemaciclib effects were extrapolated using a favorable, intermediate and unfavorable effect scenario.</p><p><strong>Results: </strong>The addition of abemaciclib in all high-risk EBC patients prolonged iDFS slightly (0.04 additional quality adjusted life years (QALYs)) and led to higher costs compared to standard ET, leading to a high incremental cost effectiveness ratio (ICER) of €1,551,876/QALY. Neither the favorable effect scenario (additional 1.09 QALYs) was cost-effective (ICER €62,935/QALY), using a willingness-to-pay threshold of €50,000/QALY. The \"MRD-guided abemaciclib\" strategy resulted in lower costs and an increase in QALYs (1.27) compared to \"standard treatment\" in the unfavorable effect scenario.</p><p><strong>Conclusion: </strong>The addition of abemaciclib to adjuvant endocrine therapy in all high-risk ER+, HER2- EBC patients is not cost-effective. However, using MRD detection to justify the addition of abemaciclib treatment dominates standard treatment in this cost-effectiveness analysis. Further evaluation of MRD detection in EBC by means of prospective clinical trials assessing clinical utility is recommended and promising in terms of cost-effectiveness.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/f0/bctt-15-147.PMC9940501.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10770594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?","authors":"Alex L Dubrava,&nbsp;Pan Su Pyae Kyaw,&nbsp;Joseph Newman,&nbsp;Jarrad Pringle,&nbsp;Justin Westhuyzen,&nbsp;Gina La Hera Fuentes,&nbsp;Thomas P Shakespeare,&nbsp;Renukadas Sakalkale,&nbsp;Noel J Aherne","doi":"10.2147/BCTT.S405719","DOIUrl":"https://doi.org/10.2147/BCTT.S405719","url":null,"abstract":"<p><strong>Purpose: </strong>Triple negative breast cancer (TNBC) is a breast carcinoma subtype that neither expresses estrogen (ER) and progesterone receptors (PR) nor the human epidermal growth factor receptor 2 (HER2). Patients with TNBC have been shown to have poorer outcomes mainly owing to the limited treatment options available. However, some studies have shown TNBC tumors expressing androgen receptors (AR), raising hopes of its prognostic role.</p><p><strong>Patients and methods: </strong>This retrospective study investigated the expression of AR in TNBC and its relationship with known patient demographics, tumor and survival characteristics. From the records of 205 TNBC patients, 36 had available archived tissue samples eligible for AR staining. For statistical purposes, tumors were classified as either \"positive\" or \"negative\" for AR expression. The nuclear expression of AR was scored by measuring the percentage of stained tumor cells and its staining intensity.</p><p><strong>Results: </strong>AR was expressed by 50% of the tissue samples in our TNBC cohort. The relationship between AR status with age at the time of TNBC diagnosis was statistically significant, with all AR positive TNBC patients being greater than 50 years old (vs 72.2% in AR negative TNBC). Also, the relationship between AR status and type of surgery received was statistically significant. There were no statistically significant associations between AR status with other tumor characteristics including \"TNM status\", tumor grade or treatments received. There was no statistically significant difference in median survival between AR negative and AR positive TNBC patients (3.5 vs 3.1 years; p = 0.581). The relationship between OS time and AR status (p = 0.581), type of surgery (p = 0.061) and treatments (p = 0.917) were not statistically significant.</p><p><strong>Conclusion: </strong>The androgen receptor may be an important prognostic marker in TNBC, with further research warranted. This research may benefit future studies investigating receptor-targeted therapies in TNBC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/72/bctt-15-359.PMC10184857.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABVS-Based Radiomics for Early Predicting the Efficacy of Neoadjuvant Chemotherapy in Patients with Breast Cancers.","authors":"Wei Jiang,&nbsp;Xiaofei Deng,&nbsp;Ting Zhu,&nbsp;Jing Fang,&nbsp;Jinyao Li","doi":"10.2147/BCTT.S418376","DOIUrl":"https://doi.org/10.2147/BCTT.S418376","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemotherapy (NAC) plays a significant role in breast cancer (BC) management; however, its efficacy varies among patients. Current evaluation methods may lead to delayed treatment alterations, and traditional imaging modalities often yield inaccurate results. Radiomics, an emerging field in medical imaging, offers potential for improved tumor characterization and personalized medicine. Nevertheless, its application in early and accurately predicting NAC response remains underinvestigated.</p><p><strong>Objective: </strong>This study aims to develop an automated breast volume scanner (ABVS)-based radiomics model to facilitate early detection of suboptimal NAC response, ultimately promoting personalized therapeutic approaches for BC patients.</p><p><strong>Methods: </strong>This retrospective study involved 248 BC patients receiving NAC. Standard guidelines were followed, and patients were classified as responders or non-responders based on treatment outcomes. ABVS images were obtained before and during NAC, and radiomics features were extracted using the PyRadiomics toolkit. Inter-observer consistency and hierarchical feature selection were assessed. Three machine learning classifiers, logistic regression, support vector machine, and random forest, were trained and validated using a five-fold cross-validation with three repetitions. Model performance was comprehensively evaluated based on discrimination, calibration, and clinical utility.</p><p><strong>Results: </strong>Of the 248 BC patients, 157 (63.3%) were responders, and 91 (36.7%) were non-responders. Radiomics feature selection revealed 7 pre-NAC and 6 post-NAC ABVS features, with higher weights for post-NAC features (min >0.05) than pre-NAC (max <0.03). The three post-NAC classifiers demonstrated AUCs of approximately 0.9, indicating excellent discrimination. DCA curves revealed a substantial net benefit when the threshold probability exceeded 40%. Conversely, the three pre-NAC classifiers had AUCs between 0.7 and 0.8, suggesting moderate discrimination and limited clinical utility based on their DCA curves.</p><p><strong>Conclusion: </strong>The ABVS-based radiomics model effectively predicted suboptimal NAC responses in BC patients, with early post-NAC classifiers outperforming pre-NAC classifiers in discrimination and clinical utility. It could enhance personalized treatment and improve patient outcomes in BC management.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/98/bctt-15-625.PMC10439736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10106022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}